Samumed, LLC, announced today that it has finalized the design of its phase 3 clinical program of lorecivivint (SM04690) for the treatment of knee osteoarthritis (OA), which will observe the effects of lorecivivint on patient-reported outcomes and disease progression. The program will be referred to as STRIDES.
Lorecivivint is a disease modifying drug that targets the WNT pathway. In the phase 2 clinical trial which included 455 participants that had knee osteoarthritis ranging from ‘moderate’ to ‘severe’, the therapy slowed the rate of cartilage breakdown, and reduced inflammation in the knee joint and successfully met the endpoints.
Phase 2 trial results were promising, as Samumed was able to show changes not only in WOMAC scores, but also changes in medial joint space width.
Samumed is currently enrolling patients for the final trial of their therapy; interested participants can find more information here.
Samumed’s press release can be found here: https://www.samumed.com/medium/image/samumed-launches-phase-3-lorecivivint-sm04690-clinical-program-in-knee-osteoarthritis_556/view.aspx